Coalition Letter Calling on the Senate Not to End the Current Development of...
July 23, 2019 Dear Chairman Grassley and Ranking Member Wyden, As organizations representing American consumers, seniors, taxpayers, and free-market advocates, we are writing to express concerns over...
View ArticleACI in Forbes: FDA Action Can Save Lives, Money
Dr. Joseph Fuhr, Jr., professor of Economics and a senior fellow at ACI, wrote a piece on how biosimilar competition could provide wider choice and cheaper access to lifesaving drugs for patients, but...
View ArticleVideo on Biosimilar Competition
ACI’s Capitol Hill event, held of December 9, 2014, discussed the importance of speeding market entry to permit biosimilar competition. That competition would give consumers increased access to lower...
View ArticlePrescription Drug Competition Means Savings
REAL CLEAR POLICY: Competition for some of the priciest drugs may soon be coming to a pharmacy near you. The new development has to do with “biologics,” which are drugs produced in living systems such...
View ArticleForbes: Biosimilar Competition Will Lower Consumer Prices
When it comes to drug prices, what’s dominating the headlines is bad news story after bad news story. Turing Pharmaceuticals raised the price of an old AIDS drug by more than 5,000 percent overnight,...
View ArticleRegulatory Uncertainty and Industry Practices Force Consumers to Overpay on...
Biopharmaceuticals are preparations synthesized from living organisms, especially a human or animal protein, such as a hormone or antitoxin that is used as a diagnostic, preventive, or therapeutic...
View ArticleBiosimilars: The Grand Experiment
Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance...
View ArticleThe Maine Wire: Congress Should Preserve Public Quality Standards for...
Congress should preserve public quality standards for biologic drugs The post The Maine Wire: Congress Should Preserve Public Quality Standards for Biologic Drugs appeared first on The American...
View ArticleBiologics Are Not A Natural Monopoly
Professors Fuhr and Blackstone, both senior fellows at ACI, published an article on biologic drugs for the Center for Biosimilars. The article is available online. The post Biologics Are Not A Natural...
View ArticleACI Joins Coalition Letter in Support of Biosimilar Competition
Today, ACI joined over two dozen groups in sending a letter to Congress in support of legislation that would increase competition for biologic drugs as a means to lower drug prices for patients. On...
View Article
